- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Xbrane Biopharma AB (XBRANE)
Xbrane Biopharma AB stock price live, this page displays ST XBRANE stock exchange data. View the XBRANE premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Xbrane Biopharma AB real time stock price chart below.
What Is the Xbrane Biopharma AB Stock Price Today?
The Xbrane Biopharma AB stock price today is 8.90.
What Is the Stock Symbol for Xbrane Biopharma AB?
The stock symbol for Xbrane Biopharma AB is ""XBRANE.""
What Stock Exchange Does Xbrane Biopharma AB Trade On?
Xbrane Biopharma AB is listed and trades on the Stockholm stock exchange.
Is Xbrane Biopharma AB a Good Stock to Buy?
Determining whether Xbrane Biopharma AB—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the XBRANE quote. (ISIN: SE0026598583)
What Is the Xbrane Biopharma AB Stock Price Today?
The Xbrane Biopharma AB stock price today is 8.90.
What Is the Stock Symbol for Xbrane Biopharma AB?
The stock symbol for Xbrane Biopharma AB is ""XBRANE.""
What Stock Exchange Does Xbrane Biopharma AB Trade On?
Xbrane Biopharma AB is listed and trades on the Stockholm stock exchange.
Is Xbrane Biopharma AB a Good Stock to Buy?
Determining whether Xbrane Biopharma AB—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the XBRANE quote. (ISIN: SE0026598583)
Stockholm
Currency in SEK
8.90
+0.03(+0.34%)
Closed·
Fair Value
An estimate of a Xbrane Biopharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
8.75
9.10
52 wk Range
8.56
38.25
XBRANE is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Xbrane Biopharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
8.759.10
52 wk Range
8.5638.25
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
XBRANE Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Xbrane Biopharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
15.50
Upside
+74.16%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell
Xbrane Biopharma AB Company Profile
Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn’s disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden.
Xbrane Biopharma AB Earnings Call Summary for Q3/2025
- Q3 revenue of SEK 10M missed SEK 77.41M forecast; stock dropped 19.02% pre-market
- FDA approval for Ximluci delayed; resubmission planned for Q1 2026
- Cash position at SEK 94M; operational runway through 2026 confirmed
- Ximluci maintains market leadership in Italy and Germany; Xdivane launch expected late 2028
- CEO expects Xdivane to potentially generate SEK 1B annually; shipments to STADA to resume Q4 2025
Last Updated: 24/10/2025, 08:46
Read Full TranscriptCompare XBRANE to Peers and Sector
Metrics to compare | XBRANE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipXBRANEPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.2x | 16.2x | −0.6x | |
PEG Ratio | −0.01 | −0.03 | 0.00 | |
Price/Book | 0.3x | 2.5x | 2.6x | |
Price / LTM Sales | 0.7x | 5.4x | 3.3x | |
Upside (Analyst Target) | 74.2% | 60.7% | 41.8% | |
Fair Value Upside | Unlock | 23.1% | 6.2% | Unlock |
Analyst Ratings
1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 15.50
(+74.16% Upside)
Earnings
Latest Release
Oct 24, 2025
EPS / Forecast
-1.17 / 1.59
Revenue / Forecast
10.05M / 77.41M
People Also Watch
FAQ
What Stock Exchange Does Xbrane Biopharma Trade On?
Xbrane Biopharma is listed and trades on the Stockholm Stock Exchange stock exchange.
What Is the Stock Symbol for Xbrane Biopharma?
The stock symbol for Xbrane Biopharma is "XBRANE."
What Is the Xbrane Biopharma Market Cap?
As of today, Xbrane Biopharma market cap is 183.41M.
What Is Xbrane Biopharma's Earnings Per Share (TTM)?
The Xbrane Biopharma EPS (TTM) is -9.29.
When Is the Next Xbrane Biopharma Earnings Date?
Xbrane Biopharma will release its next earnings report on 19 Feb 2026.
From a Technical Analysis Perspective, Is XBRANE a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Xbrane Biopharma Stock Split?
Xbrane Biopharma has split 3 times.
How Many Employees Does Xbrane Biopharma Have?
Xbrane Biopharma has 26 employees.
What is the current trading status of Xbrane Biopharma (XBRANE)?
As of 03 Dec 2025, Xbrane Biopharma (XBRANE) is trading at a price of 8.90, with a previous close of 8.90. The stock has fluctuated within a day range of 8.75 to 9.10, while its 52-week range spans from 8.56 to 38.25.
What Is Xbrane Biopharma (XBRANE) Price Target According to Analysts?
The average 12-month price target for Xbrane Biopharma is SEK15.5, with a high estimate of SEK17 and a low estimate of SEK14. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +74.16% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.